Matthew Davids, MD, MMSc, of the Dana-Farber Cancer Institute, shared his hopes for chronic lymphocytic leukemia (CLL) treatment and research in 2023.
Dr. Davids hopes to continue to “optimize therapy at an individual level” for patients with CLL. This is important, he said, as the “regimens we have now with novel agents are effective, but they’re a little bit one-size-fits-all.”
For example, some treatment regimens are one year for all patients with CLL, Dr. Davids said.
“I think that as we move into the new year and beyond, [we will be] trying to develop more individualized patient-specific regimens, based on their responses, based on [minimal residual disease], based on their genomic characteristics,” he said. “That’s going to really help to make sure that we’re not undertreating certain patients and also not overtreating other patients [and will allow us] to really optimize the duration of therapy.